Skip to main content

Main menu

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • COVID-19 and Rheumatology
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • JRheum Supplements
  • Services

User menu

  • My Cart
  • Log In

Search

  • Advanced search
The Journal of Rheumatology
  • JRheum Supplements
  • Services
  • My Cart
  • Log In
The Journal of Rheumatology

Advanced Search

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • COVID-19 and Rheumatology
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • Follow jrheum on Twitter
  • Visit jrheum on Facebook
  • Follow jrheum on LinkedIn
  • Follow jrheum on YouTube
  • Follow jrheum on Instagram
  • Follow jrheum on RSS
ReplyCorrespondence

Dr. Tam, et al, reply

STEVEN HO-MAN LAM, JIAYUN SHEN and LAI-SHAN TAM
The Journal of Rheumatology September 2018, 45 (9) 1330-1332; DOI: https://doi.org/10.3899/jrheum.180439
STEVEN HO-MAN LAM
Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Shatin, Hong Kong.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
JIAYUN SHEN
Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Shatin, Hong Kong.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
LAI-SHAN TAM
Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Shatin, Hong Kong.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for LAI-SHAN TAM
  • For correspondence: lstam@cuhk.edu.hk
  • Article
  • Figures & Data
  • Info & Metrics
  • References
  • PDF
  • eLetters
PreviousNext
Loading

To the Editor:

We thank Haroon, et al for their comments1. Their study demonstrated suboptimal performances of established cardiovascular (CV) risk scores in identifying asymptomatic coronary artery disease as confirmed by coronary computed tomography angiography (CCTA) among patients with psoriatic arthritis (PsA). The results were in line with our study based on carotid subclinical atherosclerosis2. However, they found that a multiplication factor of 1.5 accurately categorizes PsA patients as having a high risk of CV diseases, presumably based on the presence of coronary atherosclerosis. To address whether this also applies to our cohort of patients with PsA, we have performed posthoc analyses by calculating the risk scores and evaluating the performances in our published CCTA study3.

Eighty-eight patients [age 50 ± 11 yrs; male: 54 (61.4%)] were included in the analyses. Demographics and clinical characteristics are described in Table 1. Eighty-four, 74, 88, and 88 patients were eligible to calculate Framingham risk score (FRS), the Atherosclerotic Cardiovascular Disease (ASCVD) score, QRISK2, and the Systematic Coronary Risk Evaluation (SCORE), respectively. Thirty-eight (45.2%), 23 (31.1%), 6 (6.8%), and 1 (1.1%) patients were classified as having high CV risks according to FRS > 10%, ASCVD > 7.5%, QRISK2 > 20%, and SCORE > 5%, respectively. After applying the European League Against Rheumatism (EULAR) multiplication factor, 51 (60.7%), 32 (43.2%), 22 (25%), and 4 (4.5%) patients were reclassified as having high CV risks, respectively. Overall plaque (P+) and mixed plaque/noncalcified plaque (MP/NCP+), identified by CCTA, were used to confirm coronary atherosclerosis. Fifty-three patients (60.2%) were P+ while 47 patients (53.4%) were MP/NCP+. In the P+ group, 56.9%, 40.4%, 9.4%, and 1.9% patients were identified as having high CV risks according to FRS > 10%, ASCVD > 7.5%, QRISK2 > 20%, and SCORE > 5%, respectively. By applying the EULAR-recommended modification to the scores, the identification rate increased to 76.5%, 53.2%, 28.3%, and 7.5%, respectively, in the P+ group (Figure 1). In the MP/NCP+ group, 53.3%, 41.5%, 10.6%, and 2.1% were identified as having CV risks, respectively. After modifying the scores, the identification rate increased to 75.6%, 53.7%, 29.8%, and 4.5%, respectively, in the MP/NCP+ group (Figure 2).

Figure 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1.

Left: Original risk scores. Right: EULAR-modified risk scores (overall plaque). EULAR: European League Against Rheumatism; ASCVD: Atherosclerotic Cardiovascular Disease (score); SCORE: Systematic Coronary Risk Evaluation.

Figure 2.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 2.

Left: Original risk scores. Right: EULAR-modified risk scores (mixed plaque/noncalcified plaque). EULAR: European League Against Rheumatism; ASCVD: Atherosclerotic Cardiovascular Disease (score); SCORE: Systematic Coronary Risk Evaluation.

View this table:
  • View inline
  • View popup
Table 1.

Demographic and clinical features of plaque− and plaque+ patients. Values are presented as n (%) or mean ± SD.

Overall, Haroon’s result was in line with our own data and indicated that the performances of the original risk scores were poor, and the EULAR-recommended modification moderately improved the performances of these risk scores in categorizing patients with PsA at higher risks of coronary atherosclerosis. Our data also support using a similar multiplication factor of 1.5 in patients with PsA to improve the performances of CV risk scores.

Footnotes

  • This work was supported by the Health and Medical Research Fund (No. 01120496).

REFERENCES

  1. 1.↵
    1. Haroon M,
    2. Szentpetery A,
    3. Dodd D,
    4. FitzGerald O
    . Modifications of cardiovascular risk scores, but not standard risk scores, improve identification of asymptomatic coronary artery disease in psoriatic arthritis. J Rheumatol 2018;45:1329–30.
    OpenUrlFREE Full Text
  2. 2.↵
    1. Shen J,
    2. Lam SH,
    3. Shang Q,
    4. Wong CK,
    5. Li EK,
    6. Wong P,
    7. et al.
    Underestimation of risk of carotid subclinical atherosclerosis by cardiovascular risk scores in patients with psoriatic arthritis. J Rheumatol 2018;45:218–26.
    OpenUrlAbstract/FREE Full Text
  3. 3.↵
    1. Shen J,
    2. Wong KT,
    3. Cheng IT,
    4. Shang Q,
    5. Li EK,
    6. Wong P,
    7. et al.
    Increased prevalence of coronary plaque in patients with psoriatic arthritis without prior diagnosis of coronary artery disease. Ann Rheum Dis 2017;76:1237–44.
    OpenUrlAbstract/FREE Full Text
PreviousNext
Back to top

In this issue

The Journal of Rheumatology
Vol. 45, Issue 9
1 Sep 2018
  • Table of Contents
  • Table of Contents (PDF)
  • Index by Author
  • Editorial Board (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about The Journal of Rheumatology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Dr. Tam, et al, reply
(Your Name) has forwarded a page to you from The Journal of Rheumatology
(Your Name) thought you would like to see this page from the The Journal of Rheumatology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Dr. Tam, et al, reply
STEVEN HO-MAN LAM, JIAYUN SHEN, LAI-SHAN TAM
The Journal of Rheumatology Sep 2018, 45 (9) 1330-1332; DOI: 10.3899/jrheum.180439

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

 Request Permissions

Share
Dr. Tam, et al, reply
STEVEN HO-MAN LAM, JIAYUN SHEN, LAI-SHAN TAM
The Journal of Rheumatology Sep 2018, 45 (9) 1330-1332; DOI: 10.3899/jrheum.180439
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
    • To the Editor:
    • Footnotes
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • References
  • PDF
  • eLetters

Related Articles

Cited By...

More in this TOC Section

  • Dr. Kitajima et al reply
  • Dr. Putman et al reply
  • Drs. Chung and McMahan reply
Show more Correspondence

Similar Articles

Content

  • First Release
  • Current
  • Archives
  • Collections
  • Audiovisual Rheum
  • COVID-19 and Rheumatology

Resources

  • Guide for Authors
  • Submit Manuscript
  • Author Payment
  • Reviewers
  • Advertisers
  • Classified Ads
  • Reprints and Translations
  • Permissions
  • Meetings
  • FAQ
  • Policies

Subscribers

  • Subscription Information
  • Purchase Subscription
  • Your Account
  • Terms and Conditions

More

  • About Us
  • Contact Us
  • My Alerts
  • My Folders
  • Privacy/GDPR Policy
  • RSS Feeds
The Journal of Rheumatology
The content of this site is intended for health care professionals.
Copyright © 2022 by The Journal of Rheumatology Publishing Co. Ltd.
Print ISSN: 0315-162X; Online ISSN: 1499-2752
Powered by HighWire